Adderall XR is the extended-release formulation of mixed amphetamine salts, combining amphetamine aspartate, amphetamine sulfate, dextroamphetamine saccharate, and dextroamphetamine sulfate in a bead-in-capsule design that releases half the dose immediately and half four hours later. The FDA approved brand Adderall XR in 2001 for ADHD in patients age 6 and older; generic versions entered the market in 2009 after the brand patent expired. Adderall XR is a Schedule II controlled substance under the Controlled Substances Act, meaning the DEA sets an annual production quota that directly affects how much of the drug manufacturers can legally make.
Generic Adderall XR is manufactured by multiple companies, including Teva, Sandoz, Amneal, Mallinckrodt, and Lannett, and it is chemically identical to the brand version. Because it is an oral, self-administered prescription drug filled at a retail pharmacy, Adderall XR is billed exclusively through Medicare Part D, never Part B, so there is no Medicare ASP rate and no HCPCS J-code for this drug. What you actually pay depends heavily on whether you use a pharmacy discount coupon, your Medicare Part D plan's formulary tier, and whether your dose strength is currently affected by the amphetamine shortage. Patients who also take the immediate-release version should compare the Adderall IR cost guide since pricing and shortage status differ by formulation.
The DEA released its 2026 Aggregate Production Quotas on January 5, 2026, raising the d,l-amphetamine quota to roughly 24.2 million grams and the lisdexamfetamine quota to roughly 51.3 million grams after public comment. Supply has improved for some strengths, but the FDA and the American Society of Health-System Pharmacists still list amphetamine mixed salts extended-release as an active shortage through mid-2026, with 15 mg, 25 mg, and 30 mg capsules the most frequently affected. Patients managing costs while dealing with the shortage should also check Medicaid income limits to see whether a near-zero copay applies to their household.
What Adderall XR Costs by Point of Pay (2026)
The price you pay depends almost entirely on WHERE you pay. The same adderall xr can cost many times more at a hospital than at your local pharmacy:
2026 Adderall XR Price by Point of Pay| Where you pay | Typical cost | Notes |
|---|
| Pharmacy counter (retail, cash, no coupon) | $220 - $350 / 30-day supply (generic) | Brand Adderall XR lists near $300 - $450/month; price varies by dose strength (5 mg - 30 mg) |
| Pharmacy counter (GoodRx / SingleCare coupon) | $17 - $45 / 30-day supply | Free coupon at goodrx.com or singlecare.com; prices vary by pharmacy and dose |
| Medicare Part D (2026) | $0 - $50 / 30-day supply, capped at $2,100/year | Usually preferred-generic tier; prior authorization and quantity limits are common |
| Commercial insurance | $10 - $60 / month after prior authorization | Some plans require step therapy through immediate-release stimulants first |
| Medicaid | $1 - $4 / prescription | Covered in all 50 states; prior authorization for stimulants is standard in most states |
Retail and coupon prices reflect 2026 GoodRx and SingleCare data and vary by dose strength (5 mg to 30 mg) and pharmacy. Medicare Part D costs depend on your plan's formulary tier and where you are in the 2026 benefit year.
Source: GoodRx 2026, SingleCare 2026, CMS Medicare Part D 2026 benefit design
Why Hospitals Charge So Much
Hospitals rarely bill Adderall XR as a major line item because most inpatient stays are unrelated to ADHD and patients continue taking a low daily capsule count. When Adderall XR does appear on an inpatient bill, it is billed at the facility's controlled-substance dispensing rate rather than the retail pharmacy price. Schedule II drugs like extended-release amphetamine require locked storage, pharmacist double-verification, and chain-of-custody logging under DEA regulations, and hospitals pass that overhead through to the drug charge.
Many hospital formularies also require a psychiatry consult before continuing an outpatient stimulant during an admission for an unrelated condition, since Adderall XR capsules cannot be crushed or split for administration through a feeding tube without pharmacist guidance. If a facility cannot administer the extended-release formula, the care team may substitute a short-acting equivalent or arrange a temporary treatment break, which your outpatient prescriber should document to avoid a coverage gap after discharge.
Patient Assistance Programs
Takeda, the manufacturer of brand Adderall XR and Mydayis, runs the Help at Hand patient assistance program for uninsured and underinsured patients. Because generic Adderall XR is already inexpensive with a discount coupon, most patients rely on pharmacy discount programs rather than manufacturer assistance, but brand-dependent patients (for example, those who cannot tolerate a generic manufacturer's inactive ingredients) have a real PAP option.
Patient assistance programs for Adderall XR| Manufacturer program | Cost / Benefit | How to apply |
|---|
| Takeda Help at Hand (brand Adderall XR / Mydayis) | Free brand medication for uninsured or underinsured patients with household income at or below 500% of the federal poverty level | helpathandpap.com |
| GoodRx / SingleCare discount coupons (generic) | $17 - $45/month for generic amphetamine salts extended-release at most major pharmacies | goodrx.com |
| Mark Cuban Cost Plus Drugs (generic) | Generic mixed amphetamine salts extended-release listed near cost plus a flat markup and pharmacy fee | costplusdrugs.com |
| NeedyMeds Drug Discount Card | Variable discount accepted at most US pharmacies | needymeds.org |
A manufacturer coupon is rarely available for controlled substances like Adderall XR, and any manufacturer savings offer that did exist would still be barred for Medicare, Medicaid, TRICARE, or VA beneficiaries under the federal anti-kickback statute (42 U.S.C. § 1320a-7b). Government-insured patients who need brand Adderall XR or Mydayis should apply for the Takeda Help at Hand PAP instead of looking for a copay card.
Source: Takeda Help at Hand, GoodRx 2026, Cost Plus Drugs, NeedyMeds.org
Medicare Part D
Medicare Part D plans cover generic Adderall XR through prescription drug formularies rather than Part B, since it is a self-administered oral capsule. Most Part D plans place generic amphetamine salts extended-release on a preferred-generic tier (commonly Tier 2), but prior authorization and quantity limits are standard for Schedule II stimulants. Plans typically require documentation of an ADHD diagnosis, and some restrict coverage to patients under a certain age unless additional clinical justification is submitted.
The 2026 Medicare Part D annual out-of-pocket cap is $2,100. Once a beneficiary spends $2,100 in true out-of-pocket costs on covered Part D drugs in a calendar year, the plan pays 100% of covered drug costs for the rest of the year. There is no drug-specific monthly cap for Adderall XR the way there is for insulin ($35/month); it falls entirely under the general annual cap. Beneficiaries who face a high upfront bill can ask their Part D plan to enroll them in the Medicare Prescription Payment Plan to spread costs evenly across the year.
Common Adderall XR Billing Errors
Adderall XR is an oral Schedule II controlled substance and is not billed with HCPCS J-codes, so billing errors are less frequent than with injectable drugs. Still, check for these issues if a bill looks too high:
- Brand billed when generic was dispensed: if the pharmacy fills with generic amphetamine salts extended-release but the claim is submitted under the brand Adderall XR NDC, the patient can be charged the higher brand-tier cost.
- Prior authorization denial billed to the patient instead of triggering an appeal: if the PA was never approved but the pharmacy dispensed anyway, the full cash price may incorrectly land on the patient.
- Wrong days-supply code (30 vs 90 days) submitted, which throws off the calculated copay and can trigger an early-refill rejection at the next fill.
- Shortage substitution billed at the wrong strength or tier: if a pharmacy substitutes one dose strength for another because of the amphetamine shortage without updating the claim, the copay may not match the actual dose dispensed.
- Extended-release Adderall XR billed under an immediate-release Adderall NDC or vice versa; the two formulations have different NDCs, different prices, and sometimes different formulary coverage rules.
Frequently Asked Questions
Is there a generic for Adderall XR?
Yes. Generic Adderall XR (amphetamine/dextroamphetamine extended-release, also called mixed amphetamine salts XR) has been available since 2009, made by Teva, Sandoz, Amneal, Mallinckrodt, Lannett, and other manufacturers. It is FDA-rated AB-equivalent to the brand, meaning it must deliver the same active ingredients at the same extended-release rate. Generic Adderall XR typically costs 80 to 95 percent less than brand Adderall XR with a pharmacy discount coupon.
How much does generic Adderall XR cost without insurance in 2026?
Generic Adderall XR costs $220 to $350 for a 30-day supply at retail cash prices in 2026, depending on the pharmacy and dose strength. With a free GoodRx or SingleCare coupon, most pharmacies fill it for $17 to $45 per month. Brand Adderall XR lists near $300 to $450 per month. Costco and Kroger Rx Savings Club typically beat Walmart's cash price for uninsured patients paying without a coupon.
How do I apply for the Takeda Help at Hand patient assistance program?
Visit helpathandpap.com or call 1-800-830-9159 to request an application. Complete the patient section, have your prescriber complete the prescribing section, and attach your most recent federal tax return as proof of income. Mail or fax the completed application to Takeda Help At Hand, P.O. Box 5727, Louisville, KY 40255-0727. Eligible patients with household income at or below 500 percent of the federal poverty level receive brand Adderall XR or Mydayis free of charge.
Can I use a manufacturer savings card for Adderall XR with Medicare?
No. Adderall XR is a Schedule II controlled substance, and manufacturer copay savings cards are rarely offered for controlled substances in the first place. Even if one existed, federal anti-kickback law bars manufacturer copay cards from being used by Medicare, Medicaid, TRICARE, or VA beneficiaries. If you have government insurance and need brand Adderall XR, apply for the Takeda Help at Hand patient assistance program instead.
What if my insurance denies coverage for Adderall XR?
Request the written denial notice, which must state the specific reason, such as a missing prior authorization or a step-therapy requirement. Ask your prescriber to submit documentation of your ADHD diagnosis and treatment history, then file a formal appeal within 60 days for Medicare Part D or up to 180 days for most commercial plans. If the internal appeal fails, you can request an external review through your state's Department of Insurance.
Does the IRA negotiated price apply to Adderall XR?
No. Adderall XR was not selected for either Round 1 or Round 2 of Medicare drug price negotiation under the Inflation Reduction Act, so there is no negotiated Maximum Fair Price for this drug. Instead, generic Adderall XR falls under the general 2026 Medicare Part D annual out-of-pocket cap of $2,100. Since the generic already costs $17 to $45 with a pharmacy coupon for most patients, IRA negotiation would have limited additional impact on this drug's price.
Does Medicare Part D cover Adderall XR?
Yes, most Medicare Part D plans cover generic Adderall XR, typically on a preferred-generic formulary tier. Prior authorization and quantity limits are standard for Schedule II stimulants, and your prescriber will need to document your ADHD diagnosis. Your total out-of-pocket cost across all Part D drugs combined is capped at $2,100 for 2026. There is no separate monthly cap for stimulants the way there is for insulin.
Is Adderall XR still in shortage in 2026?
Yes. As of mid-2026, the FDA and the American Society of Health-System Pharmacists still list amphetamine mixed salts extended-release as an active shortage, with 15 mg, 25 mg, and 30 mg capsules the most frequently affected. The DEA raised its 2026 amphetamine production quota in January, which has improved availability for some strengths, but backlog recovery has been slower than manufacturers initially estimated. If your pharmacy is out of stock, ask about other locations, a partial fill, or a therapeutically equivalent alternative from your prescriber.
